Omnicell, Inc. (NASDAQ:OMCL) Given Average Rating of "Hold" by Analysts

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has received a consensus rating of "Hold" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $50.83.

Several equities analysts have recently weighed in on OMCL shares. Bank of America restated a "neutral" rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Wells Fargo & Company increased their price objective on Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a research report on Monday, October 14th. Barclays lifted their target price on Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Benchmark reissued a "buy" rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Finally, Craig Hallum lifted their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st.

Omnicell Price Performance

Shares of OMCL stock traded down $2.32 during midday trading on Friday, reaching $50.14. 466,706 shares of the company were exchanged, compared to its average volume of 555,021. The company's 50 day moving average price is $43.89 and its two-hundred day moving average price is $36.13. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.95 and a current ratio of 1.05. The company has a market cap of $2.31 billion, a P/E ratio of -128.56, a PEG ratio of 50.54 and a beta of 0.81. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its stake in shares of Omnicell by 2.9% during the second quarter. Arizona State Retirement System now owns 12,853 shares of the company's stock valued at $348,000 after purchasing an additional 357 shares during the last quarter. Texas Permanent School Fund Corp increased its stake in shares of Omnicell by 1.2% in the 1st quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company's stock valued at $1,158,000 after buying an additional 479 shares during the period. Diversified Trust Co raised its position in shares of Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company's stock worth $416,000 after acquiring an additional 494 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after acquiring an additional 553 shares during the period. Finally, Louisiana State Employees Retirement System boosted its holdings in Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company's stock valued at $625,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.